Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$48.00
â–²(67.25% Upside)
Action:ReiteratedDate:01/24/26
The score is driven primarily by improving financial performance (strong margins, profitability gains, and accelerating free cash flow) and supportive technical momentum (clear uptrend with positive MACD). These positives are meaningfully tempered by expensive valuation (P/E 122.1) and moderate leverage.
Positive Factors
High Gross Margin and Operational Efficiency
Sustained gross margins near 80% reflect strong unit economics typical of proprietary biologics. High margin structure supports continued R&D investment and commercialization spending without immediate margin pressure, providing durable profitability buffer as products scale.
Negative Factors
Moderate Leverage
Debt-to-equity near 0.7 is manageable but elevated for a growth biotech; it can constrain strategic flexibility and increase interest obligations. Over the medium term this may limit capacity for additional R&D spending or acquisitions without raising equity or refinancing under less favorable terms.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin and Operational Efficiency
Sustained gross margins near 80% reflect strong unit economics typical of proprietary biologics. High margin structure supports continued R&D investment and commercialization spending without immediate margin pressure, providing durable profitability buffer as products scale.
Read all positive factors
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.94B
Dividend YieldN/A
Average Volume (3M)488.12K
Price to Earnings (P/E)42.4
Beta (1Y)1.10
Revenue Growth48.38%
EPS GrowthN/A
CountryHK
Employees1,117
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding110,781,920
10 Day Avg. Volume755,126
30 Day Avg. Volume488,121
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)3.81
Price to Sales (P/S)3.24
P/FCF Ratio18.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$57.72Price Target Upside101.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.73
Revenue Forecast (FY)HK$1.84B
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-re...
How the Company Makes Money
Biocytogen Pharmaceuticals generates revenue primarily through the development and commercialization of its therapeutic products, which include monoclonal antibodies. The company earns money by partnering with other pharmaceutical firms for drug d...
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.19B | 980.45M | 716.91M | 533.88M | 354.56M | 253.54M |
| Gross Profit | 946.48M | 761.52M | 506.03M | 391.75M | 247.44M | 166.99M |
| EBITDA | 382.48M | 303.80M | -97.87M | -465.86M | -378.12M | -328.64M |
| Net Income | 132.21M | 33.54M | -382.95M | -602.16M | -545.58M | -542.97M |
Balance Sheet | ||||||
| Total Assets | 2.49B | 2.42B | 2.45B | 2.80B | 2.30B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 486.84M | 381.18M | 408.09M | 611.27M | 566.45M | 957.41M |
| Total Debt | 614.18M | 570.28M | 544.11M | 415.28M | 89.80M | 463.80M |
| Total Liabilities | 1.59B | 1.58B | 1.66B | 1.65B | 1.05B | 868.28M |
| Stockholders Equity | 892.04M | 834.06M | 785.89M | 1.15B | 1.25B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 338.66M | 174.12M | -203.26M | -543.94M | -564.45M | -531.73M |
| Operating Cash Flow | 385.07M | 211.25M | -76.65M | -303.27M | -365.78M | -225.31M |
| Investing Cash Flow | -188.05M | -137.12M | -100.28M | -153.74M | -84.13M | -188.18M |
| Financing Cash Flow | -165.85M | -92.03M | -37.82M | 587.20M | 219.44M | 868.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Positive
28.70
Price Trends
50.63
Positive
41.70
Positive
32.90
Positive
Market Momentum
2.46
Negative
64.17
Neutral
79.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 28.7 is below the 20-day moving average (MA) of 55.59, below the 50-day MA of 50.63, and below the 200-day MA of 32.90, indicating a bullish trend. The MACD of 2.46 indicates Negative momentum. The RSI at 64.17 is Neutral, neither overbought nor oversold. The STOCH value of 79.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$25.94B | 42.36 | 15.32% | ― | 48.38% | ― | |
54 Neutral | HK$18.02B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.63B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$20.03B | -25.84 | -17.26% | ― | 964.40% | 65.90% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
63.50
51.28
419.64%
HK:1672
Ascletis Pharma, Inc.
16.98
11.88
232.94%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.73
79.82%
HK:2162
Keymed Biosciences, Inc.
71.35
32.35
82.95%
HK:2171
CARsgen Therapeutics Holdings Ltd.
18.39
7.23
64.78%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.98
-1.51
-17.79%
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen Deepens Acepodia Tie-Up With Option-Based Deal on Next-Gen Bispecific ADCs
Jan 12, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has expanded its collaboration with U.S.-based Acepodia Inc. through a newly signed option and license agreement to support the structured evaluation and potential licensing of two bispecific antibody...
Biocytogen Announces Resignation of Non-Executive Director Wei Yiliang
Dec 31, 2025
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that non-executive director Wei Yiliang has resigned from the board, and from his roles on the Audit Committee and the Strategy Development Committee, effective 31 December 2025, citing othe...
Biocytogen Pharmaceuticals Outlines Board Composition and Committee Roles
Dec 31, 2025
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has announced the current composition of its board of directors, which includes executive, non-executive, independent non-executive and an employee director, led by Chairman, CEO and General Manager Dr...
Biocytogen H Shares Added to Shanghai and Shenzhen-Hong Kong Stock Connect
Dec 24, 2025
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed pharmaceutical company, announced that its H shares have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Co...
Biocytogen Pharmaceuticals Announces Board Composition and Committee Roles
Dec 9, 2025
Biocytogen Pharmaceuticals has announced the composition of its board of directors, detailing the roles and functions of each member. This update on the board’s structure, including the establishment of four committees, is significant for st...
Biocytogen Pharmaceuticals Enhances Governance with New Audit Committee
Dec 9, 2025
Biocytogen Pharmaceuticals has established an Audit Committee under its board of directors to enhance corporate governance. This committee is responsible for reviewing financial disclosures, supervising audit work, and ensuring effective internal ...
Biocytogen Pharmaceuticals Enhances Governance with New Nomination Committee
Dec 9, 2025
Biocytogen Pharmaceuticals has established a Nomination Committee under its board of directors to regulate the appointment of directors and senior management, aiming to enhance corporate governance. This move is expected to strengthen the company&...
Biocytogen Pharmaceuticals Enhances Governance with New Committee
Dec 9, 2025
Biocytogen Pharmaceuticals has established a Remuneration and Evaluation Committee under its board of directors to improve its corporate governance structure. This committee is tasked with formulating evaluation standards and reviewing remuneratio...
Biocytogen Pharmaceuticals Strengthens Strategic Framework with New Committee
Dec 9, 2025
Biocytogen Pharmaceuticals has established a Strategy Committee under its board of directors to enhance strategic development, improve investment decision-making, and strengthen corporate governance. This move aims to bolster the company’s l...
Biocytogen Pharmaceuticals Completes A Shares Issuance and Announces Leadership Changes
Dec 9, 2025
Biocytogen Pharmaceuticals has successfully completed the issuance of A Shares, which will be listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange starting December 10, 2025. This strategic move is expected to enhance the company...
Biocytogen’s Partner IDEAYA Receives FDA Clearance for IDE034 Clinical Trial
Dec 5, 2025
Biocytogen Pharmaceuticals announced that its partner, IDEAYA Biosciences, has received FDA clearance for an IND application to initiate a Phase 1 clinical trial of IDE034, a bispecific B7H3/PTK7 antibody-drug conjugate. This milestone underscores...
Biocytogen Pharmaceuticals Sets A Share Offering Price and Size
Nov 26, 2025
Biocytogen Pharmaceuticals has announced the determination of the offer size and price for its A Share Offering, with plans to issue 47,500,000 new A Shares at RMB26.68 per share. This strategic move, following preliminary price consultations, aim...
Biocytogen Pharmaceuticals Submits A Share Prospectus Amid Financial Growth
Nov 19, 2025
Biocytogen Pharmaceuticals has submitted a prospectus for the initial public offering of A shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The financial information reveals a significant improvement in the company’s f...
Biocytogen Pharmaceuticals Announces A Share Issuance on Shanghai Stock Exchange
Nov 19, 2025
Biocytogen Pharmaceuticals has announced the preliminary price consultation period for its proposed issuance of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company plans to issue 47,500,000 new A Shares, represent...
Biocytogen Pharmaceuticals Approves Key Resolutions at 2025 EGM
Nov 19, 2025
Biocytogen Pharmaceuticals held its first extraordinary general meeting of 2025, where several key resolutions were approved by shareholders. The meeting, conducted both physically and virtually, saw the approval of the proposed issuance of A Shar...
Biocytogen Pharmaceuticals to Issue A Shares on Sci-Tech Board
Nov 3, 2025
Biocytogen Pharmaceuticals has announced plans to issue A Shares and list them on the Sci-Tech Board, with the approval process completed by the Shanghai Stock Exchange and CSRC. The proceeds from this issuance will be used to fund various project...
Biocytogen Pharmaceuticals Announces 2025 Extraordinary General Meeting
Nov 3, 2025
Biocytogen Pharmaceuticals has announced its 2025 first extraordinary general meeting, scheduled for November 19, 2025. The meeting will address several key resolutions, including the proposed issuance of A Shares and amendments to company article...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.